Gold Fields Limited (Gold Fields) (NYSE:GFI) on 20 October 2014 published updated production guidance for the Group for the September 2014 quarter (Q3 2014). Attributable gold equivalent production for the quarter is expected to be approximately 559,000 ounces at All-in Sustaining Costs (AISC) of US$1,074/oz and All-in Costs (AIC) of US$1,096/oz. Gold Fields Ltd. (NYSE:GFI) belongs to Basic Materials sector. Its net profit margin is -7.30% and weekly performance is 17.57%. On last trading day company shares ended up $4.35. Gold Fields Ltd. (NYSE:GFI) distance from 50-day simple moving average (SMA50) is 12.24%.

Sprint Corporation (NYSE:S) is shuffling top executive positions, as CEO Marcelo Claure continues his turnaround efforts for the struggling carrier. The first executive to leave the carrier will be Chief Marketing Officer Jeff Hallock, who had been responsible for Sprint’s highly disliked and confusing “Framily plan” campaign. Sprint Corporation (NYSE:S) shares decreased -3.05% in last trading session and ended the day at $4.76. S Gross Margin is 44.50% and its return on assets is -2.30%. Sprint Corporation (NYSE:S) quarterly performance is -13.45%.

Flowserve Corporation’s (NYSE:FLS) board of directors recently authorized a replenished share buyback worth $500 million, reaffirming the company’s policy of returning capital to its shareholders. This apart, the company declared quarterly cash dividend of 16 cents a share, payable on Jan 9, 2015 to shareholders on record as of Dec 26, 2014. On 18 November, Flowserve Corp. (NYSE:FLS) shares moved up 0.68% and was closed at $66.50. FLS EPS growth in last 5 year was 5.80%. Flowserve Corp. (NYSE:FLS) year to date (YTD) performance is -15.10%.

Keryx Biopharmaceuticals (NASDAQ:KERX) previously proclaimed that the U.S. Food and Drug Administration has permitted the trade name Auryxia for its FDA official ferric citrate. Auryxia, an iron based phosphate binder, was authorized by the FDA to manage serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014. Ron Bentsur, CEO of Keryx, stated that they were eager to collect FDA authorization of the trade name Auryxia. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) ended the last trading day at $15.54. Company weekly volatility is calculated as 4.18% and price to cash ratio as 12.09. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) showed a weekly performance of -2.51%.

HEICO Corporation (NYSE:HEI.A) (NYSE:HEI) on 13 November 2014 reported that its 3D PLUS subsidiary supplied mission critical components on the European Space Agency’s (ESA) Rosetta program which yesterday successfully landed a robotic probe on a comet for the first time in history. HEICO Corporation (NYSE:HEI) shares moved up 0.08% in last trading session and ended the day at $51.58. HEI Gross Margin is 35.70% and its return on assets is 7.80%. HEICO Corporation (NYSE:HEI) quarterly performance is -0.90%.